TIDMTRX

RNS Number : 0742Y

Tissue Regenix Group PLC

10 May 2021

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

Director/PDMR Shareholding

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that on 7 May 2021, David Cocke, Chief Financial Officer, acquired 2,821,000 Ordinary Shares in the Group at a price of 0.64 pence per share for a total consideration of GBP18,054.40.

As a result, David Cocke's beneficial interest in the Company is 2,821,000 Ordinary Shares, representing 0.04% of the total issued share capital.

 
      Notification of a Transaction pursuant to Article 19(1) 
       of Regulation (EU) No. 596/2014 
  1   Details of the person discharging managerial responsibilities 
       / person closely associated 
     ---------------------------------------------------------------- 
 a)   Name                      David Cocke 
     ------------------------  -------------------------------------- 
 2    Reason for the notification 
     ---------------------------------------------------------------- 
 a)   Position/status           Chief Financial Officer 
     ------------------------  -------------------------------------- 
 b)   Initial notification      Initial notification 
       /Amendment 
     ------------------------  -------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ---------------------------------------------------------------- 
 a)   Name                      Tissue Regenix Group plc 
     ------------------------  -------------------------------------- 
 b)   LEI                         213800PNOD5UHQUFJI36 
     ------------------------  -------------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ---------------------------------------------------------------- 
 a)   Description 
       of the financial           Ordinary Shares of 0.1p each 
       instrument, 
       type of instrument 
     ------------------------  -------------------------------------- 
 b)   Identification            GB00B5SGVL29 
       code 
     ------------------------  -------------------------------------- 
 c)   Nature of the             Acquisition of Ordinary Shares 
       transaction 
     ------------------------  -------------------------------------- 
 d)   Price(s) and                Price   Volume 
       volume(s)                   0.64p   2,821,000 
                                          ---------- 
     ------------------------  -------------------------------------- 
 d)   Aggregated 
       information 
       - Aggregated               2,821,000 
       volume                     GBP18,054.40 
       - Price 
     ------------------------  -------------------------------------- 
 e)   Date of the               7 May 2021 
       transaction 
     ------------------------  -------------------------------------- 
 f)   Place of the              London Stock Exchange, AIM Market 
       transaction 
     ------------------------  --------------------------------------

For more information:

 
 Tissue Regenix Group plc                                    www.tissueregenix.com 
  David Cocke, Chief Financial Officer                             Via Walbrook PR 
 
 Stifel Nicolaus Europe Limited (Nominated Adviser         Tel: +44(0)20 7710 7600 
  and Broker) 
  Ben Maddison / Alex Price 
 Walbrook PR Ltd                                          Tel: +44 (0)20 7933 8780 
  Alice Woodings / Paul McManus                       TissueRegenix@walbrookpr.com

About Tissue Regenix ( www.tissueregenix.com )

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies(R), a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGIGDUBUBDGBG

(END) Dow Jones Newswires

May 10, 2021 05:00 ET (09:00 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Tissue Regenix Charts.
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Tissue Regenix Charts.